I’d expect significant redundancy costs to form part of H1 results, the wages piece won’t make for happy reading and potentially EBITDA % at its lowest performance ebb.
However now with a more streamlined management structure, Apiam might start to achieve a better yield if revenue per Vet is on the rise, assuming it’s been able to obtain quality income generating Vets for its clinic network. H2 might see the start of a positive recovery. Watch this space.
- WE.
Ann: H1 FY24 Reporting Date and Investor Webinar Notification, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.010(2.50%) |
Mkt cap ! $75.41M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.0¢ | 39.0¢ | $100.8K | 249.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 37500 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 11997 | 1 |
View Market Depth
| Last trade - 15.26pm 16/06/2025 (20 minute delay) ? |
| AHX (ASX) Chart |